Biotech firm Windtree Therapeutics plans to purchase up to $700 million in BNB to enhance its balance sheet, following BNB's new all-time high price. Based in Warrington, Pennsylvania, Windtree has announced its intention to raise $520 million through a $500 million equity line of credit and a $20 million stock-purchase agreement. The CEO emphasized that stockholder approval is essential for these additional BNB purchases. BNB, currently the fifth-largest cryptocurrency by market capitalization, hit a peak of $808 recently before experiencing a slight decline. This move reflects a growing trend where publicly traded companies, inspired by firms like Strategy, are diversifying their treasury assets with cryptocurrencies beyond just Bitcoin. The rising interest in crypto assets signifies a shift in how companies are leveraging digital currencies to boost their stock performance, with Windtree's stock recently experiencing a significant increase following the announcement.

Source đź”—